CardioDx Launches Gene Test For Obstructive Coronary Disease
This article was originally published in The Gray Sheet
CardioDx is gradually rolling out its Corus CAD gene expression test, which quantifies the likelihood of obstructive coronary artery disease in patients with stable chest pain and no previous history of cardiac disease
You may also be interested in...
CardioDx raises $58 million for heart test marketing. OmniGuide gets $35 million for surgical laser products. More financings.
CardioNet buys CardioCore Lab. HeartWare gears for HVAD rollout. Zimmer prevails in Genzyme patent case. CardioDx gains Corus CAD heart test Medicare coverage. More news briefs.
Cameron Health raises $107 million